(redirected from Vivitrol)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Vivitrol: Suboxone


A synthetic opioid antagonist, C20H23NO4, used in its hydrochloride form to treat addiction to alcohol and to opioid drugs such as heroin.

[Blend of naloxone and tre- (probably alteration of tri-, from the three carbon atoms of the propyl group that distinguishes it from naloxone, of which it is a congener).]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.


(Pharmacology) a narcotic antagonist, similar to morphine, used chiefly in the treatment of heroin addiction
[C20: from N-al(lylnor)ox(ymorph)one, + the arbitrary insertion of -trex-]
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014


(nælˈtrɛk soʊn)

a nonaddictive substance, C20H23NO4, used in the treatment of heroin addiction and opiate overdose.
[1970–75; by rearrangement of parts of its chemical name]
Random House Kernerman Webster's College Dictionary, © 2010 K Dictionaries Ltd. Copyright 2005, 1997, 1991 by Random House, Inc. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.naltrexone - an oral antagonist against the action of opiates
narcotic antagonist - an antagonist used to counteract the effects of narcotics (especially to counteract the depression of respiration)
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.


n naltrexona
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
Currently in our community, Wisconsin Medical Assistance, BadgerCare, and managed care health maintenance organizations (HMOs) all authorize and pay for Vivitrol. In addition, most commercial insurances include it either as a pharmacy or medical benefit.
Alkermes Inc., maker of naltrexone under the name Vivitrol, has a head start on the monitoring and support question from the drug's current label for alcohol abuse treatment, which states: "Alcohol-dependent patients, including those taking Vivitrol, should be monitored for the development of depression or suicidal thinking.
Last December, the Food and Drug Administration gave "approvable" status to Vivitrol, a long-acting, once-monthly formulation of naltrexone.
As previously reported, Morgan Stanley analyst David Risinger downgraded Alkermes to Underweight from Equal Weight after he reduced projections for the company's key growth franchise, Vivitrol for addiction disorder.
Whether it is disulfiram (Antabuse), naltrexone (ReVia), injectable naltrexone (Vivitrol), acamprosate (Campral), the above-mentioned Suboxone or even methadone, I'm just not seeing the successes one would hope from such interventions.
as Vivitrol, is an opioid antagonist administered once monthly by intramuscular injection and is approved in the United States for the treatment of alcohol dependence.
His "blue sky valuation," which has Vivitrol and the schizophrenia franchise generating peak combined sales of more than $1.5B, is $61 per share.
Golden admits that he is "not in a good position to give good information on Vivitrol" because he doesn't use it on patients.
The company makes Vivitrol, a monthly injectable drug that blocks the effects of opioids and reduces cravings.
decided to include treatment professionals in long-term recovery in its "Touchpoints" recovery support campaign for Vivitrol, its medication to treat alcohol dependence, the Cambridge, Mass., company hit on something important.
A total of 74 patients who participated in a 4-year trial comparing two doses of injectable extended-release naltrexone (Vivitrol) with placebo or a 3-year trial comparing the injectable drug with the oral formulation agreed to participate in an extension phase involving high- or low-dose naltrexone and a questionnaire, according to Dr.
The analyst noted that Vivitrol and Aristada continue to experience modest growth and therefore should not drive shares higher.